drugset / Trial / NCT06994143
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
Non-randomizedSequentialOpen-labelTreatment
Summary
A Phase I, open-label study of CLN-978 in patients with treatment-refractory rheumatoid arthritis.
Timeline
- Start
- 2025-05-19
- Primary completion
- 2027-12-30
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CLN-978 | Other / unclassified | — | Subcutaneous |